Infectious Disease Diagnostics Market Worth $23.4 billion by 2025.

The disease global infectious disease diagnostics is expected to grow at a CAGR of 5.9% from 2018 to 2025 to reach $23.4 billion by 2025.

On the basis of product, assays and kits market commanded the largest share of the global infectious disease diagnostics market in 2018. This segment is also expected to grow at the highest CAGR during the forecast period due to the increasing prevalence of infectious diseases, raising awareness among the population to identify the diseases, and increasing use of kits and reagents to identify the organism causing various diseases in lesser time and cost.

immunodiagnostics accounted for the largest share of the infectious disease diagnostics market in 2018. This is owing to the increasing use of immunoassays in POC infectious disease testing, development of novel tests, rising trend of automation, increasing awareness about health and fitness, and reduced complications associated with the instruments. Immunodiagnostic technologies are majorly used for the detection of infectious diseases. Radioimmunoassay and Enzyme-Linked Immunosorbent Assay (ELISA) were the predominant techniques used for the diagnosis. Lower complexity, high-sensitivity, and its ease of use are the major factors contributed to the growth of the immunodiagnostic technology for the diagnosis of infectious diseases. However, polymerase chain reaction (PCR) segment is expected to grow significantly during the forecast period. Increasing adoption of the molecular diagnostic technology in place of antigen testing by immunoassays, increasing chances of detecting the minute amount of protein biomarkers with high specificity; and growing probability of detecting infectious diseases to mitigate the result with high accuracy is expected to drive the growth of the molecular diagnostic technology in the infectious disease diagnostics market.

Browse the in-depth report: https://www.meticulousresearch.com/product/infectious-disease-diagnostics-market-4976/

Hepatitis segment held the largest share of the infectious disease diagnostics market. This is mainly attributed to the increasing prevalence of hepatitis B & C infection, rising susceptibility of the geriatric population, growing awareness among the population, and the increasing availability of various molecular diagnostic technologies. Hepatitis is a result of the inflammation of the liver which is the key organ that processes nutrients, filters the blood, and fights the infections. Hepatitis is most commonly caused by a viral infection. Various types of diagnostic tests are designed to identify the hepatitis virus and thereby providing both prevention and treatment services to the patient population. Early detection of this virus HBV and HCV infection enables the patient to receive necessary care and treatment to prevent the progression of liver diseases. Traditional and molecular techniques are used for the identification of the hepatitis virus.

Hospital/clinical laboratories segment held the major share in 2018. This is primarily attributed to the increasing number of outpatients for infectious diseases, increasing hospital expenditures, growing technological advancement for diagnostic platforms in hospitals, and an increasing number of skilled professionals. The hospital/clinical laboratories process more samples in very less time due to the well-equipped system and the presence of skilled professionals. Hospital/clinical laboratories are commonly used by the diagnosis of samples obtained from the hospital inpatients as well as the outpatients who are being seen by the hospital-affiliated physicians. A hospital lab consists of various sections for testing which focuses on particular methods or techniques for the investigation of the sample specimens.

Request sample report on :https://www.meticulousresearch.com/request-sample-report/cp_id=4976

Asia Pacific region is expected to be the fastest growing geographic market for infectious disease diagnostics market with countries, such as China, Japan, India, and Singapore among others are being the largest contributors to the growth of the market. Additionally, rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, need to manage the growing burden of infectious diseases, and government efforts to improve the accessibility of diagnostic services are expected to equally influence the overall growth of the infectious disease diagnostics market during the forecast period.

The major players operating in the global infectious disease diagnostics market are Abbott Laboratories (U.S.), Danaher (U.S.), Bio-Rad Laboratories (U.S.), bioMérieux SA (France), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), DiaSorin S.p.A. (Italy), Meridian Bioscience, Inc. (U.S.), Quidel Corporation (U.S.), and Thermo Fisher Scientific Inc. (U.S.) among others.

Contact Us:
Khushal
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

Office No-202, 203,204,205,206; 2nd Floor, Pushpak Business Hub,
Wakad, Pimpri-Chinchwad, 411057 India.

This release was published on openPR.